You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Merck
Express Scripts
Harvard Business School
McKinsey

Last Updated: February 26, 2021

DrugPatentWatch Database Preview

Ibritumomab tiuxetan - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for ibritumomab tiuxetan

Identify potential brand extensions & biosimilar entrants

SponsorPhase
National Cancer Institute (NCI)Phase 3
University of California, DavisPhase 2
Spectrum Pharmaceuticals, IncPhase 3

See all ibritumomab tiuxetan clinical trials

Recent Litigation for ibritumomab tiuxetan

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
GENENTECH, INC. v. CELLTRION, INC.2018-01-11
GENENTECH, INC. v. SANDOZ, INC.2017-12-20

See all ibritumomab tiuxetan litigation

PTAB Litigation
PetitionerDate
2017-12-20

See all ibritumomab tiuxetan litigation

Company Disclosures: US Patents for ibritumomab tiuxetan

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial Idec Pharmaceuticals Corporation (San Diego, CA) 2015-04-07 RX Orphan company
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial IDEC Pharmaceuticals Corporation (San Diego, CA) 2015-07-07 RX Orphan company
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial 2015-12-01 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for ibritumomab tiuxetan

These patents were identified by searching patent claims

Supplementary Protection Certificates for ibritumomab tiuxetan

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB04/025 United Kingdom   Start Trial PRODUCT NAME: IBRITUMOMAB COMPRISING A CHELATING AGENT FOR YTTRIUM (90); REGISTERED: UK EU/1/03/264/001 20040116
04C/016 Belgium   Start Trial PRODUCT NAME: IBRITUMOMAB; AUTHORISATION NUMBER AND DATE: EU/1/03/264/001 20040119
2016 00031 Denmark   Start Trial PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Colorcon
Baxter
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.